Rational design of MyD88 inhibitors--new pathways to inflammatory control: an interview with Dr. Claudio Sette by Helene F. Rosenberg.
Sette
Claudio
C
University of Rome "Tor Vergata", Rome, Italy.
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D040761:Biomimetic Materials / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D015195:Drug Design; D006801:Humans; D051379:Mice; D008958:Models, Molecular; D053594:Myeloid Differentiation Factor 88 / Q000037:antagonists & inhibitors* / Q000276:immunology; D009842:Oligopeptides / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D013329:Structure-Activity Relationship; D051217:Toll-Like Receptor 9 / Q000276:immunology
D000893:Anti-Inflammatory Agents; C507779:MYD88 protein, human; C507780:Myd88 protein, mouse; D053594:Myeloid Differentiation Factor 88; D009842:Oligopeptides; C495371:TLR9 protein, human; C495370:Tlr9 protein, mouse; D051217:Toll-Like Receptor 9